Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

First-in-human trial of a recombinant vesicular stomatitis virus HIV-1 Gag vaccine

Oct. 14, 2013

First report of HIV proviral DNA level modulation in response to AGS-004 immunotherapy

Oct. 11, 2013

Immunogenicity and efficacy of HIVAX vaccine: results of a first-in-human study

Oct. 10, 2013

VAC-3S vaccine: first-in-human safety, dose and immunization results

Oct. 9, 2013

Bristol-Myers Squibb prepares and tests HIV attachment inhibitors

Oct. 9, 2013

Viriom reports data from international trial of HIV drug candidate

Oct. 9, 2013

AIC-292 shows potent anti-HIV-1 activity in vivo and in first-in-human studies

Oct. 4, 2013

Valneva enters into license agreement with International AIDS Vaccine Initiative

Oct. 3, 2013

First demonstration of vaccine-mediated elimination of SIV infection

Oct. 3, 2013

New HIV integrase inhibitors disclosed by Bristol-Myers Squibb

Sep. 30, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...